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Abstract	50 
Context	51 
Subclinical hypothyroidism has been associated with increased risk of coronary heart disease 52 
(CHD), particularly with thyrotropin levels ≥10.0 mIU/L. The measurement of thyroid antibodies 53 
helps predict progression to overt hypothyroidism, but it is unclear whether thyroid auto-54 
immunity independently affects CHD risk. 55 
Objective	56 
To compare the CHD risk of subclinical hypothyroidism with and without thyroid peroxidase 57 
antibodies (TPOAb). 58 
Data	sources	and	Study	selection	59 
MEDLINE and EMBASE search from 1950 to 2011 for prospective cohorts, reporting baseline 60 
thyroid function, antibodies and CHD outcomes. 61 
Data	extraction	62 
Individual data of 38,274 participants from 6 cohorts for CHD mortality, followed for 460,333 63 
person-years, and 33,394 participants from 4 cohorts for CHD events. 64 
Data	synthesis	65 
Among 38,274 adults (median age 55 years, 63% women), 1691 (4.4%) had subclinical 66 
hypothyroidism, of whom 775 (45.8%) had positive TPOAb. During follow-up, 1436 participants 67 
died of CHD and 3285 had CHD events. Compared to euthyroid individuals, age- and gender-68 
adjusted risks of CHD mortality in subclinical hypothyroidism were similar among individuals 69 
with and without TPOAb (HR=1.15, 95%CI 0.87 to 1.53, vs. HR=1.26, CI 1.01 to 1.58, p for 70 
interaction 0.62), as were risks of CHD events (HR=1.16, CI 0.87 to 1.56 vs. HR=1.26, CI 1.02 to 71 
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1.56, p for interaction 0.65). Risks of CHD mortality and events increased with higher 72 
thyrotropin, but within each stratum, risks did not differ by TPOAb status. 73 
Conclusions	74 
CHD risk associated with subclinical hypothyroidism did not differ by TPOAb status, suggesting 75 
that biomarkers of thyroid auto-immunity do not add independent prognostic information for 76 
CHD outcomes. 77 
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Introduction	78 
The prevalence of subclinical hypothyroidism increases with age and is highest among older 79 
women (1, 2). Controversy persists as to whether population-wide screening and treatment of 80 
subclinical thyroid dysfunction are warranted (1, 3). Current evidence about the risks of 81 
subclinical hypothyroidism remains limited (1, 3), and randomized clinical trials on relevant 82 
clinical outcomes have not been performed to date (1, 4). Our recent individual participant data 83 
analysis found that subclinical hypothyroidism (defined as elevated thyrotropin level [4.5-19.9 84 
mIU/L] and normal free thyroxin [T4] level) was associated with coronary heart disease (CHD) 85 
mortality and CHD events, with stronger association for those with thyrotropin (also known as 86 
thyroid-stimulating hormone, TSH) ≥10.0 mIU/L (5). 87 
The presence of thyroid antibodies predicts the risk of progression from subclinical to overt 88 
hypothyroidism (6-9). Among 1877 subjects (56% women), both raised TSH level and the 89 
presence of thyroid antibodies at baseline were associated with development of hypothyroidism 90 
over 20-year follow-up (6). Among 92 women (mean age 50.7 years) with subclinical 91 
hypothyroidism followed for 9 years, the incidence of overt hypothyroidism increased from 92 
23.2% to 58.5% with the presence of anti-microsomal antibodies (p=0.03) (10). Although 93 
recommendations in guidelines about measuring thyroid antibodies to better identify patients who 94 
should receive levothyroxine replacement differ (1, 3), physicians include thyroid antibody status 95 
in their decision of whether or not to treat subclinical hypothyroidism (11). 96 
Because the presence of thyroid antibodies is associated with more progression from subclinical 97 
to overt hypothyroidism (6-10) and overt hypothyroidism with increased cardiovascular risk (12), 98 
one may infer that subclinical hypothyroidism with positive thyroid antibodies might be also 99 
associated with increased risks of CHD mortality or events, although this has not been studied in 100 
appropriately sized studies with clinical outcomes. Indeed, thyroid antibodies have been 101 
associated with increased markers of endothelial dysfunction that may lead to atherosclerosis 102 
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(13). However, it is unknown whether the presence of thyroid antibodies in subclinical 103 
hypothyroidism predicts patient-relevant cardiovascular outcomes, such as CHD events. Only a 104 
few previous studies have reported clinical cardiovascular outcomes, with conflicting data (14-105 
18). The studies had also limited power with a relatively low number of events and did not 106 
provide subgroup analyses (e.g. by TSH levels or age). 107 
We therefore aimed to compare the risks of CHD mortality and events associated with subclinical 108 
hypothyroidism by thyroid antibody status using individual participant data from our Thyroid 109 
Studies Collaboration (5, 19, 20). 110 
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Methods	111 
Data	sources	and	Study	selection	112 
As previously described (5, 19, 20), we identified prospective cohort studies and collected their 113 
individual participant data based on a systematic literature review of MEDLINE and EMBASE 114 
databases from 1950 to 30 June 2011, with no language restriction, and screened bibliographies 115 
of selected articles (Appendix Methods). We included studies with a priori criteria: full-text 116 
published longitudinal cohort studies, reporting baseline levels of thyroid function (TSH and T4) 117 
and antibodies, with a control euthyroid group and prospective follow-up of cause-specific 118 
mortality and CHD outcomes. We excluded studies where only participants taking thyroid 119 
medications (anti-thyroid drugs, thyroxin, or amiodarone) or participants with only overt 120 
hypothyroidism (high TSH and low T4 levels) were included. 121 
Data	extraction	and	Quality	assessment	122 
Investigators from each original study were invited to join the Thyroid Studies Collaboration and 123 
to share individual participant data, as previously described (5, 19, 20). We collected 124 
demographic data, TSH, free T4 or total T4 in one study (14), thyroid antibodies, baseline 125 
cardiovascular risk factors (i.e. blood pressure, cigarette smoking status, total cholesterol level, 126 
diabetes mellitus), body mass index (weight in kilograms divided by squared height in meters 127 
[kg/m2]), cardiovascular and thyroid medication use, and outcome data on CHD events and 128 
mortality. We assessed study quality using previous criteria (21) after collecting additional 129 
information from study authors: methods of outcome adjudication and ascertainment, accounting 130 
for confounders, and completeness of follow-up. 131 
Data	synthesis	and	Analysis	132 
Similar to our previous analyses (5, 19, 20), we used a uniform TSH cutoff level, based on an 133 
expert consensus meeting of our Thyroid Studies Collaboration (International Thyroid 134 
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Conference, Paris, 2010), expert reviews (1) and previous large cohorts (15, 22). Euthyroidism 135 
was defined as TSH 0.45-4.49 mIU/L, and subclinical hypothyroidism as TSH 4.5-19.9 mIU/L 136 
and normal T4 level. Similar to our previous analysis on subclinical hypothyroidism (5), we used 137 
a study-specific TSH reference range of 6.0-21.5 mIU/L for participants in the Whickham Survey 138 
(14), because of the first-generation TSH radioimmunoassay in this study that gives higher 139 
measured TSH values than current assays (23). For participants in the Study of Health in 140 
Pomerania (24), a iodine fortification program was started a few years before inclusion; thus a 141 
TSH reference range of 0.25-2.12 mIU/L was used as suggested for iodine-deficient areas (25); 142 
we further performed a sensitivity analysis excluding this study. Without this study-specific TSH 143 
range, a large group of participants would have been considered subclinically hyperthyroid 144 
(n=706, 18.4%) and very few subclinically hypothyroid (n=13, 0.4%). For T4 level, we used 145 
study- and method-specific cutoff values (Appendix Table 1), as this measurement shows greater 146 
inter-method variation than TSH assays. Eight participants among 1691 with TSH 4.5-19.9 147 
mIU/L had missing T4 values (Appendix Table 1): 7 of these participants had TSH values 148 
ranging from 4.6 to 6.4 mIU/L and one a TSH of 15 mIU/L. As previously performed (5, 19, 20), 149 
we assumed that these participants had subclinical hypothyroidism because most adults with this 150 
degree of TSH elevation have subclinical rather than overt hypothyroidism (2). We performed a 151 
sensitivity analysis excluding those participants with missing T4 values. 152 
Thyroid antibodies were measured by different assays in the original cohorts and we used assay-153 
specific cutoff values (Appendix Table 1). In two older cohorts, levels of anti-microsomal 154 
antibodies (22) and thyroid anticytoplasmic antibodies (14) were available instead of the more 155 
precise thyroid peroxidase antibodies (TPOAb) in the four other cohorts (26). Therefore, we 156 
conducted a sensitivity analysis excluding the two studies relying on older assays for thyroid 157 
antibodies. We also performed sensitivity analyses excluding thyroid medication users at 158 
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baseline, then at baseline and during follow-up, as well as analyses limited to participants with 159 
TSH ≥10.0 mIU/L. 160 
Outcomes were CHD events and CHD mortality. Similar to our previous analyses (5, 19), we 161 
used more homogenous definitions to limit the outcome heterogeneity observed in a previous 162 
study-level analysis (21). Similar to the Framingham risk score (27), we limited cardiovascular 163 
mortality to CHD mortality or sudden death (Appendix Table 1). We defined CHD events as non-164 
fatal myocardial infarction or CHD death (equivalent to “hard events” in the Framingham risk 165 
score (27)) or hospitalization for angina or coronary revascularization (22). Data on heart failure 166 
(HF) outcome were available from one study (22) with thyroid antibodies. Incident HF events 167 
were assessed in participants free of HF at baseline and adjudicated every 6 months based on 168 
interview, review of medical records, and other support documents without knowledge of thyroid 169 
status (28). 170 
Statistical	analyses	171 
Similar to our previous studies (5, 19, 20), we analyzed the association between subclinical 172 
hypothyroidism with and without antibodies and each outcome using separate Cox proportional 173 
hazard models of individual participant data from each cohort (SAS 9.2, SAS Institute Inc, Cary, 174 
NC; Stata 12.1, StataCorp, College Station, TX). Pooled estimates for each outcome were 175 
calculated with random-effects models based on the inverse variance model as recommended in 176 
two-stage individual participant data analyses (29, 30). Results were summarized using forest 177 
plots (Review Manager 5.1.7, Nordic Cochrane Centre, Copenhagen, Denmark). To assess 178 
heterogeneity across studies, we applied the I2 statistic, which measures the inconsistency across 179 
studies attributable to heterogeneity instead of chance alone (31). We analyzed the potential 180 
additional effect of TPOAb to predict CHD outcomes in subclinical hypothyroidism by 181 
interaction tests: we compared pooled estimates of risk of CHD outcomes for TPOAb-positive 182 
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subclinical hypothyroidism vs. euthyroidism and TPOAb-negative subclinical hypothyroidism vs. 183 
euthyroidism using interaction tests. 184 
Primary analyses were adjusted for age and sex (some traditional cardiovascular risk factors 185 
being potential mediators of CHD risk associated with subclinical hypothyroidism (12)), then 186 
further adjusted for cardiovascular risk factors (systolic blood pressure, smoking status, total 187 
cholesterol, diabetes), body mass index, lipid-lowering and antihypertensive medications. To 188 
explore potential sources of heterogeneity, we performed pre-defined subgroup and sensitivity 189 
analyses as in our previous analyses (5, 19, 20). We conducted stratified analyses by age, sex, and 190 
TSH category representing them as aggregate forest plots to summarize our findings. For some 191 
strata with participants but no event in subgroup analyses, we used penalized likelihood methods 192 
(32) to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). We checked the 193 
proportional hazard assumption using graphical methods and the Schoenfeld test (33). To assess 194 
potential publication bias, we used age and sex-adjusted funnel plots and the Egger test (34). 195 
Thyroid antibody status, subclinical hypothyroidism and the risk of coronary heart disease 11 
November 2, 2017 
Results	196 
We identified reports of 6 prospective cohorts meeting all inclusion criteria (Appendix Figure 1) 197 
comprising 38,274 adults (median age 55 years, 62.9% women) recruited from the general 198 
population. 36,583 were euthyroid and 1691 (4.4%) had subclinical hypothyroidism, of whom 199 
775 (45.8%) had positive TPOAb (Table 1). Median follow-up was 12.2 years (interquartile 200 
range 11.2-13.1 years) for a total of 460,333 person-years, with a loss to follow-up rate <5% in 201 
all included studies. 202 
During follow-up, 1436 participants died of CHD in the whole sample, and 3285 CHD events 203 
occurred among 33,394 participants from 4 cohorts having data on CHD events (14-16, 22) 204 
(Table 2). In age and sex-adjusted analyses compared to euthyroid individuals, risks of CHD 205 
mortality were similar among those with TPOAb-positive subclinical hypothyroidism (HR 1.15, 206 
CI 0.87 to 1.53) and those with TPOAb-negative subclinical hypothyroidism (HR 1.26, CI 1.01 to 207 
1.58, p for interaction 0.62) (Appendix Figure 2). The risks of CHD events were also similar 208 
between subclinically hypothyroid TPOAb-positive and negative individuals (HR 1.16, CI 0.87 to 209 
1.56 vs. HR 1.26, CI 1.02 to 1.56, respectively, p for interaction 0.65) (Appendix Figure 2). As 210 
heterogeneity was present across studies for CHD events (I2=49%), but not for CHD mortality 211 
(I2=0%), we subsequently assessed potential differences of risks according to subgroups. In 212 
stratified analyses, risks for CHD mortality and events increased with higher TSH levels, 213 
although with limited statistical evidence for a trend; power was more limited for these subgroup 214 
analyses compared to our previous analyses with 11 cohorts (5). However, at each TSH level, 215 
risks did not differ by TPOAb status (Figure 1). Risks differed slightly according to sex and age, 216 
though the interaction terms were not statistically significant (p for interaction ≥0.39 for sex and 217 
>0.05 for age categories, Table 2). 218 
Sensitivity analyses yielded comparable results (Table 3). The exclusion of thyroid medication 219 
users at baseline or during follow-up yielded similar results including after further excluding 2 220 
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studies without data on thyroid medication during follow-up (16, 35) (data not shown). Risks 221 
were similar in multivariate models accounting for cardiovascular risk factors, lipid-lowering and 222 
antihypertensive medications, or body mass index. Limiting analyses to studies with recent 223 
thyroid antibodies assays or to participants with TSH ≥10.0 mIU/L yielded overall higher risks of 224 
CHD mortality and events but estimates did not differ according to TPOAb status (Appendix 225 
Table 2). 226 
When analyzing data from the four cohorts that measured TPOAb in all participants irrespective 227 
of TSH (n=9151) (14, 15, 24, 35), the overall prevalence of TPOAb positivity was 6.5% 228 
(Appendix Table 3). In age and sex-adjusted analyses, CHD mortality risk was similar in the 229 
population with positive TPOAb compared to those with negative TPOAb (HR 1.09, CI 0.75 to 230 
1.58), as well as for CHD events (HR 1.19, CI 0.93 to 1.53). Stratified analyses by gender yielded 231 
similar results (both p for interaction ≥0.40). This post-hoc analysis showed similar results to the 232 
main analyses of subclinical hypothyroidism according to TPOAb status, with lower power due 233 
to the number of participants. 234 
One study had data on thyroid antibodies and incident HF events (22). Among the 2985 older 235 
participants, 695 (27.5%) individuals in euthyroid state and 116 (25.3%) with subclinical 236 
hypothyroidism developed HF. Age- and gender-adjusted analyses stratified by thyroid 237 
antibodies showed similar HF risks among those with thyroid antibody-positive subclinical 238 
hypothyroidism (HR 0.84, CI 0.61 to 1.14) and those with thyroid antibody-negative subclinical 239 
hypothyroidism (HR 1.01, CI 0.79 to 1.28, p for interaction 0.37). Power was insufficient to 240 
assess HF risks stratified both by thyroid antibodies and TSH levels or other subgroups. 241 
The proportional hazard assumption was consistent across studies (all p>0.10). We found limited 242 
evidence of publication bias with visual assessment of age and gender-adjusted funnel plots and 243 
the Egger test for CHD mortality (p=0.50) and CHD events (p=0.060).  244 
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Discussion	245 
In this analysis of data from more than 38,000 individuals recruited in 6 prospective cohorts, risks 246 
of CHD mortality and CHD events associated with subclinical hypothyroidism did not differ 247 
according to TPOAb status. In stratified analyses, risks increased with higher TSH levels but did 248 
not differ by TPOAb status at each TSH level. 249 
These results are consistent with most previous studies. In a recent analysis, LeGrys et al. found 250 
no association between the presence of TPOAb in subclinical hypothyroidism and subsequent 251 
myocardial infarction events among post-menopausal women (17). Similar results were also 252 
found for reports of single cohorts included in the Thyroid Studies Collaboration, such as the 253 
Whickham Survey (14), the HUNT Study (Nord-Trøndelag Health Study) (16), and the Busselton 254 
Health Study (15). However, in the Rotterdam Study, the presence of positive TPOAb in 255 
subclinical hypothyroidism was associated with prevalent myocardial infarction compared to 256 
euthyroid women (18), but there were not enough events for prospective analysis of this 257 
association (16 first incident myocardial infarctions over 4.6 years) (21). 258 
Because thyroid auto-immunity has been associated with a higher risk for progression from 259 
subclinical to overt hypothyroidism (6-10), progression of atherosclerosis (18, 36), and overt 260 
hypothyroidism with increased cardiovascular risk (12), one may expect that TPOAb-positive 261 
subclinical hypothyroidism would also be associated with more CHD mortality or events. This 262 
was not confirmed in our analysis. A possible explanation is that physicians may rely on TPOAb 263 
status to decide whether to start levothyroxin treatment, as recommended by some current 264 
guidelines (3), and that such treatment may have reduced the risk of CHD. However, our 265 
sensitivity analysis yielded similar results after excluding participants who started thyroid 266 
medication during follow-up. Moreover, some of the etiologies of TPOAb-negative subclinical 267 
hypothyroidism may also increase CHD risk. For example, adiposity is probably one of the 268 
causes of elevated TSH levels (37), and adiposity is also associated with increased CHD risk 269 
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(38). However, adjusting for BMI (our best measure of adiposity) did not change the present 270 
results. To summarize, the presence of TPOAb may be a good marker of progression of 271 
subclinical to overt hypothyroidism, but a poor marker for stratification of who will develop 272 
cardiovascular complications (3). Our analyses show that any risk of CHD is mediated through 273 
thyroid dysfunction (5), without an independent contribution from autoimmune dysfunction. This 274 
adds to current knowledge about the pathophysiology of thyroid-related CHD and has clinical 275 
implications since thyroid dysfunction is a treatable risk factor and thyroid autoimmunity is not. 276 
Our study is the largest to investigate the association between TPOAb status and cardiovascular 277 
risk in participants with subclinical hypothyroidism. The analysis of individual participant data 278 
from several studies allowed us to analyze subgroup data that have less potential bias than study-279 
level meta-analyses. Study strengths are the inclusion of time-to-event analyses and the use of 280 
standardized definitions of predictors, outcomes and adjustment for confounding factors (29). 281 
The study had the following limitations. Participants were mainly Caucasians, except for one 282 
cohort including Brazilians of Japanese descent (35), so our results may not apply to other 283 
populations. Second, thyroid function tests were performed only at baseline, which is a limitation 284 
of most published cohort studies. The number of participants with subclinical hypothyroidism at 285 
baseline that normalized to euthyroid state over time or those who progressed to overt 286 
hypothyroidism is unknown, although previous studies showed a low proportion of progression 287 
over 20 years of follow-up (14). Moreover, recent studies found similar results for risk of CHD 288 
using single or repeated TSH measurements among the elderly within the Cardiovascular Health 289 
Study (28). In a recent study of the oldest old, there were no associations between baseline levels 290 
and 13-year change in TSH, FT4 levels, and TPOAb positivity and mortality (39). Third, older 291 
thyroid antibodies assays were used in two included cohorts (anti-microsomal antibodies (22) and 292 
thyroid cytoplasmic antibodies (14)), but sensitivity analyses excluding cohorts with older assays 293 
yielded similar results. Because thyroglobulin antibodies (TgAb) were not available in the three 294 
Thyroid antibody status, subclinical hypothyroidism and the risk of coronary heart disease 15 
November 2, 2017 
largest cohorts, there was insufficient power to examine the risks associated with thyroglobulin 295 
antibodies. However, the lack of TgAb in our analyses should not be a major limitation, because 296 
most people (70%) who had positive TgAb in NHANES III also had positive TPOAb (2). 297 
Moreover, both in NHANES III (cross-sectional (2)) and the Busselton Health Study 298 
(longitudinal analysis (40)), positive TgAb alone in the absence of positive TPOAb was not a 299 
predictor of thyroid disease. Fourth, during follow-up of individuals with subclinical 300 
hypothyroidism, 90 out of the 294 participants with positive thyroid antibodies (30.6%) and 67 of 301 
the 378 participants with negative thyroid antibodies (17.7%) were treated with thyroxine. 302 
However, sensitivity analyses excluding thyroid medication users yielded similar results. 303 
Current guidelines for the management of subclinical hypothyroidism are conflicting about 304 
measuring TPOAb to target treatment in patients with subclinical hypothyroidism (1, 3). 305 
Although the presence of TPOAb in subclinical hypothyroidism predicts the evolution to overt 306 
hypothyroidism, we found that it did not predict CHD outcomes associated with subclinical 307 
hypothyroidism, suggesting that biomarkers of thyroid auto-immunity do not add independent 308 
prognostic information on CHD outcomes. Thyroid antibodies may be useful for investigating the 309 
etiology of subclinical hypothyroidism and to predict the potential evolution to overt 310 
hypothyroidism. Because of the absence of prediction of TPOAb status on CHD risks in 311 
subclinical hypothyroidism, other biomarkers should be examined to identify patients at increased 312 
cardiovascular risk. Randomized clinical trials are needed to clarify whether the presence of 313 
thyroid antibodies to target treatment in patients predicts a larger benefit of levothyroxine 314 
treatment of subclinical hypothyroidism on clinical outcomes (4, 41). 315 
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Table	1	
Baseline characteristics of individuals with euthyroidism or subclinical hypothyroidism with measured thyroid antibodies 
Study Description of study sample No Median age 
(range) * 
Women, no 
(%) 
Subclinical 
hypothyroidism, 
no (%) † 
Subclinical 
hypothyroidism 
with positive 
TPOAb, no (%) ‡ 
Thyroid 
medication at 
baseline / during 
follow-up, no (%) § 
Follow-up || 
Start Median duration 
(IQR) / Person-years 
United States          
Cardiovascular 
Health Study 
(22) 
Community-dwelling adults 
with Medicare eligibility in 
4 US communities 
2984 71 (64-100) 1788 (59.9%) 458 (15.3%) 187 (40.8%) 0 (0.0%) / 
146 (4.9%) 
1989-1990 13.9 (8.6-16.4) 
/ 36,584 
Europe          
HUNT Study 
(16) 
Adults living in Nord-
Trøndelag County, Norway 
26,062 54 (20-97) 17,562 (67.4%) 822 (3.2%) 429 (52.2%) 0 (0.0%) / 
NA 
1995-1997 12.3 (11.8-12.9) 
/ 305,106 
Study of Health 
in Pomerania 
(24) 
Adults living in Western 
Pomerania, Germany 
3845 49 (20-81) 1945 (50.6%) 106 (2.8%) 32 (30.2%) 206 (5.4%) / 
262 (6.8%) 
1997-2001 10.0 (9.3-10.7) 
/ 37,209 
Whickham 
Survey (14) 
Adults living in and near 
Newcastle upon Tyne, UK 
2406 46 (18-92) 1284 (53.4%) 124 (5.2%) 41 (33.1%) 99 (4.1%) / 
73 (3.0%) 
1972-1974 19.0 (15.0-20.0) 
/ 39,088 
Australia          
Busselton 
Health Study 
(15) 
Adults living in Busselton, 
Western Australia 
1997 51 (18-90) 983 (49.2%) 89 (4.5%) 60 (67.4%) 15 (0.8%) / 
33 (1.7%) 
1981 20.0 (19.5-20.0) 
/ 35,437 
Brazil          
Brazilian 
Thyroid Study 
(35) 
Adults of Japanese descent 
living in São Paulo, Brazil 
980 56 (30-92) 518 (52.9%) 92 (9.4%) 26 (28.3%) 0 (0.0%) / 
NA 
1999-2000 7.3 (7.1-7.5) 
/ 6909 
Overall  38,274 55 (18-100) 24,080 (62.9%) 1691 (4.4%) 775 (45.8%) 
320 (0.8%) / 
514 (1.3%) 1972-2001 
12.2 (11.2-13.1) 
/ 460,333 
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Table	1	(footnotes)	
Abbreviations: IQR, interquartile range (25th-75th percentiles); NA, data not available; TPOAb, thyroid peroxidase antibodies. 
* Participants younger than 18 years were excluded. 
† The Whickham Survey used a 1st generation TSH assay, which gives higher values than current assays, thus a TSH range of 6.0 to 21.5 mIU/L was 
used for subclinical hypothyroidism (14). Participants in SHIP had iodine supplementation a few years before inclusion, thus a TSH reference range 
(0.25-2.12 mIU/L) was used as suggested (25). 
‡ No. participants with subclinical hypothyroidism and a positive TPOAb status. The percentage relates to all participants with subclinical 
hypothyroidism (shown immediately to the left of this column). 
§ Data on thyroid medication use (thyroxine, antithyroid drugs) were not available for 2 and 1468 participants of the Whickham Survey (14) at 
baseline and during follow-up, respectively, and for all participants of the HUNT Study (Nord-Trøndelag Health Study) (16) and the Brazilian 
Thyroid Study (35) during follow-up. 
|| For all cohorts, we used the maximal follow-up data that were available, which might differ from previous reports for some cohorts. 
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Table	2	
Age- and sex-adjusted analyses for the association of subclinical hypothyroidism (SH) with coronary heart disease (CHD) mortality and CHD 
events, according to measured thyroid antibody status 
 CHD Mortality * 
 Euthyroidism 
SH with negative 
TPOAb status 
SH with positive 
TPOAb status 
SH with negative 
TPOAb vs. 
euthyroidism 
SH with positive 
TPOAb vs. 
euthyroidism 
P for 
interaction  Events Participants Events Participants Events Participants HR (95% CI) HR (95% CI) 
Total population 1301 36,583 85 916 50 775 1.26 (1.01, 1.58) 1.15 (0.87, 1.53) 0.62 
Sex          
Men 720 13,720 38 322 19 152 1.16 (0.84, 1.62) 1.38 (0.80, 2.37) 0.59 
Women 581 22,863 47 594 31 623 1.41 (1.04, 1.90) 1.21 (0.84, 1.73) 0.53 
P for interaction       0.39 0.70  
Age ‡          
18-49 years 50 11,704 1 173 1 162 2.41 (0.55, 10.61) § 4.88 (1.20, 19.96) § 0.50 
50-64 years 210 11,210 10 221 4 196 2.71 (1.12, 6.53) § 1.83 (0.72, 4.63) § 0.55 
65-79 years 805 9630 64 432 34 344 1.49 (1.15, 1.93) 1.04 (0.74, 1.47) 0.10 
≥ 80 years 212 1381 10 88 11 41 0.60 (0.32, 1.13) § 1.71 (0.92, 3.19) § 0.02 
P for trend       0.057 0.12  
TSH          
0.45-4.49 mIU/L 1301 36,583     1 (reference) 1 (reference)  
4.5-6.9 mIU/L   69 733 23 475 1.39 (1.09, 1.78) 1.11 (0.71, 1.74) 0.39 
7.0-9.9 mIU/L   11 133 13 173 1.09 (0.47, 2.54) 
§ 1.28 (0.75, 2.18) § 0.75 
10.0-19.9 mIU/L   5 50 14 120 1.64 (0.75, 3.56) 
§ 1.70 (1.01, 2.86) § 0.94 
P for trend       0.33 0.047  
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Table	2	(cont.)	
Age- and sex-adjusted analyses for the association of subclinical hypothyroidism (SH) with coronary heart disease (CHD) mortality and CHD 
events, according to measured thyroid antibody status 
 CHD Events 
† 
 Euthyroidism 
SH with negative 
TPOAb status 
SH with positive 
TPOAb status 
SH with negative 
TPOAb vs. 
euthyroidism 
SH with positive 
TPOAb vs. 
euthyroidism 
P for 
interaction  Events Participants Events Participants Events Participants HR (95% CI) HR (95% CI) 
Total population 2995 31,903 174 774 116 717 1.26 (1.02, 1.56) 1.16 (0.87, 1.56) 0.65 
Sex          
Men 1609 11,392 79 273 36 133 1.16 (0.92, 1.46) 0.99 (0.66, 1.48) 0.51 
Women 1386 20,511 95 501 80 584 1.27 (1.02, 1.59) 1.18 (0.94, 1.48) 0.65 
P for interaction       0.58 0.46  
Age ‡          
18-49 years 322 11,697 6 122 7 161 1.44 (0.66, 3.14) 2.13 (1.00, 4.55) 0.48 
50-64 years 660 10,160 21 164 10 185 1.72 (1.10, 2.69) § 0.98 (0.38, 2.54) § 0.29 
65-79 years 1686 8627 123 400 84 330 1.20 (1.00, 1.45) 1.11 (0.79, 1.56) 0.69 
≥ 80 years 306 1380 24 88 15 41 1.04 (0.68, 1.57) § 1.54 (0.63, 3.75) § 0.44 
P for trend       0.33 0.65  
TSH          
0.45-4.49 mIU/L 2995 31,903     1 (reference) 1 (reference)  
4.5-6.9 mIU/L   130 615 64 437 1.19 (0.96, 1.46) 1.06 (0.82, 1.37) 0.50 
7.0-9.9 mIU/L   28 118 28 165 1.22 (0.75, 2.00) 1.07 (0.74, 1.56) 0.67 
10.0-19.9 mIU/L   16 41 24 115 2.60 (1.43, 4.74) 1.23 (0.61, 2.47) 0.11 
P for trend       0.002 0.57  
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Table	2	(footnotes)	
Abbreviations: CI, confidence interval; CHD, coronary heart disease; HR, hazard ratio (all age- and sex-adjusted); NA, data not applicable; SH, 
subclinical hypothyroidism; TPOAb, thyroid peroxidase antibodies. 
* 21 participants were excluded from the analyses of CHD mortality because of missing cause of death. 
† The Study of Health in Pomerania (24) and the Brazil Thyroid Study (35) were not included in CHD events analysis because follow-up data were 
only available for death. 
‡ These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata. 
§ Strata from specific studies were excluded when there were <5 events or an empty comparison group. 
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Table	3	
Sensitivity analyses for the association of subclinical hypothyroidism (SH) with coronary heart disease (CHD) mortality and CHD events, according 
to measured thyroid antibody status 
  CHD Mortality 
  Euthyroidism SH with negative TPOAb status 
SH with positive 
TPOAb status 
SH with negative 
TPOAb vs. 
euthyroidism 
SH with positive 
TPOAb vs. 
euthyroidism P for 
interaction   Events Participants Events Participants Events Participants HR (95% CI) HR (95% CI) 
All eligible studies             
Random-effects model 1301 36,583 85 916 50 775 1.26 (1.01, 1.58) 1.15 (0.87, 1.53) 0.62 
Fixed-effects model 1301 36,583 85 916 50 775 1.26 (1.01, 1.58) 1.15 (0.87, 1.53) 0.62 
Excluding participants             
Excluding those with missing T4 * 1301 36,583 84 912 49 771 1.26 (1.00, 1.57) 1.13 (0.85, 1.51) 0.56 
Excluding thyroid medication users at baseline † 1279 36,289 83 899 49 766 1.26 (1.01, 1.58) 1.13 (0.85, 1.51) 0.53 
Excluding thyroid medication users at baseline or 
during follow-up † 1269 36,076 78 834 44 682 1.34 (1.07, 1.69) 1.28 (0.94, 1.72) 0.79 
Excluding studies             
Excluding studies with older thyroid antibody 
assays ‡ 711 31,775 32 562 17 547 1.56 (1.09, 2.23) 1.21 (0.75, 1.94) 0.41 
Excluding study with recent iodine 
supplementation (24) 1247 32,844 84 842 50 743 1.26 (1.01, 1.57) 1.15 (0.86, 1.53) 0.62 
Excluding studies with shifted TSH reference range 
(14, 24) 1024 30,562 74 759 44 702 1.30 (1.02, 1.65) 1.13 (0.84, 1.53) 0.47 
Further adjustments in multivariate (MV) models §             
Adjusted for age, sex, systolic blood pressure, 
smoking status, total cholesterol, and diabetes at 
baseline (MV model 1) 
1290 36,441 84 914 50 772 1.27 (1.01, 1.59) 1.16 (0.88, 1.55) 0.62 
MV model 1 + lipid-lowering and antihypertensive 
medications 1287 36,373 84 912 50 772 1.26 (1.01, 1.58) 1.18 (0.89, 1.57) 0.72 
MV model 1 + body mass index 1276 36,234 82 908 48 776 1.25 (1.00, 1.57) 1.13 (0.84, 1.50) 0.59 
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Table	3	(cont.)	
Sensitivity analyses for the association of subclinical hypothyroidism (SH) with coronary heart disease (CHD) mortality and CHD events, according 
to measured thyroid antibody status 
  CHD Events 
  Euthyroidism SH with negative TPOAb status 
SH with positive 
TPOAb status 
SH with negative 
TPOAb vs. 
euthyroidism 
SH with positive 
TPOAb vs. 
euthyroidism P for 
interaction   Events Participants Events Participants Events Participants HR (95% CI) HR (95% CI) 
All eligible studies             
Random-effects model 2995 31,903 174 774 116 717 1.26 (1.02, 1.56) 1.16 (0.87, 1.56) 0.65 
Fixed-effects model 2995 31,903 174 774 116 717 1.20 (1.03, 1.41) 1.08 (0.90, 1.31) 0.39 
Excluding participants             
Excluding those with missing T4 * 2995 31,903 172 770 115 713 1.26 (1.01, 1.56) 1.17 (0.86, 1.59) 0.70 
Excluding thyroid medication users at baseline † 2967 31,805 172 768 115 711 1.24 (1.02, 1.51) 1.15 (0.87, 1.54) 0.67 
Excluding thyroid medication users at baseline or 
during follow-up † 2934 31,695 155 715 93 638 1.25 (1.06, 1.47) 1.12 (0.88, 1.41) 0.46 
Excluding studies             
Excluding studies with older thyroid antibody 
assays ‡ 1599 27,138 54 422 40 489 1.49 (1.13, 1.95) 1.28 (0.74, 2.22) 0.63 
Excluding study with recent iodine 
supplementation (24) NA NA NA NA NA NA NA NA   
Excluding studies with shifted TSH reference range 
(14, 24)  2557 29,664 157 693 106 677 1.29 (0.97, 1.71) 1.12 (0.80, 1.59) 0.53 
Further adjustments in multivariate (MV) models §             
Adjusted for age, sex, systolic blood pressure, 
smoking status, total cholesterol, and diabetes at 
baseline (MV model 1) 
2978 31,784 173 772 116 715 1.28 (1.02, 1.59) 1.17 (0.86, 1.59) 0.65 
MV model 1 + lipid-lowering and antihypertensive 
medications 2974 31,716 173 770 116 714 1.29 (1.03, 1.61) 1.22 (0.88, 1.70) 0.78 
MV model 1 + body mass index 2940 31,587 169 766 114 709 1.23 (1.01, 1.50) 1.17 (0.87, 1.58) 0.78 
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Table	3	(footnotes)	
Abbreviations: CI, confidence interval; CHD, coronary heart disease; HR, hazard ratio (all age and sex-adjusted, unless stated otherwise); MV, 
multivariate; NA, not applicable; SH, subclinical hypothyroidism. 
* 8 participants were excluded in this analysis: Cardiovascular Health Study 6, Whickham Survey 1 and Busselton Health Study 1. 
† The numbers of thyroid medication users (thyroxine, antithyroid drugs) at baseline and during follow-up are reported in Table 1. 
‡ Studies with older thyroid auto-antibodies assays were excluded: anti-microsomal antibodies in the Cardiovascular Health Study (22) and thyroid 
cytoplasmic antibodies in the Whickham Survey (14). 
§ Some participants were excluded from MV models because of lack of data on covariates. 
